{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T03:03:53Z","timestamp":1788231833851,"version":"build-2803163510"},"reference-count":12,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"9","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Clin Cancer Inform"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:sec>\n            <jats:title>PURPOSE<\/jats:title>\n            <jats:p>Accurate survival data are critical for high-quality outcomes research. It has been documented that mortality data capture in the real-world setting may be prone to missingness. Our study sought to evaluate the validity of a composite real-world mortality variable compared with the National Death Index (NDI) as the gold standard.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>METHODS<\/jats:title>\n            <jats:p>This was a retrospective, observational research study of patients with hematologic malignancies treated in the United States. Adult patients diagnosed with one of the following cancers between January 1, 2012, and December 31, 2020, were included: AML, chronic lymphocytic leukemia, diffuse large B-cell lymphoma, follicular lymphoma, marginal zone lymphoma, multiple myeloma, and myelodysplastic syndrome. Validation metrics (sensitivity, specificity, positive predictive value [PPV], and negative predictive value [NPV]) and date concordance (exact, \u00b17, 15, and 30 days) were assessed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS<\/jats:title>\n            <jats:p>The final study population included N = 21,565 patients across seven cancer types. Validation metrics showed high sensitivity (87.8%), specificity (95.7%), PPV (90.9%), and NPV (94.1%) when comparing the composite real-world mortality variable with the NDI. Exact date concordance was observed in 88.0% of patients, and concordance rates for 7-, 15-, and 30-day intervals were 93.1%, 93.8%, and 94.3%, respectively.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION<\/jats:title>\n            <jats:p>Our study found that a composite mortality variable leveraging multiple data sources yields high validity when compared against the gold-standard NDI. Given evidence highlighting the challenges of mortality data documentation in the real-world setting, the use of a composite mortality variable can provide significant benefits in quality of documentation and research results.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1200\/cci-24-00233","type":"journal-article","created":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T20:00:22Z","timestamp":1744833622000},"update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":4,"title":["Validation of a Composite Real-World Mortality Variable Among Patients With Hematologic Malignancies Treated in the United States"],"prefix":"10.1200","author":[{"given":"Sharlene","family":"Dong","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6901-0782","authenticated-orcid":true,"given":"Ankit","family":"Kansagra","sequence":"additional","affiliation":[{"name":"Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2510-6536","authenticated-orcid":false,"given":"Gurbakhash","family":"Kaur","sequence":"additional","affiliation":[{"name":"Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Barcellos","sequence":"additional","affiliation":[{"name":"COTA, Inc, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Belli","sequence":"additional","affiliation":[{"name":"COTA, Inc, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura L.","family":"Fernandes","sequence":"additional","affiliation":[{"name":"COTA, Inc, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Hansen","sequence":"additional","affiliation":[{"name":"COTA, Inc, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Ambrose","sequence":"additional","affiliation":[{"name":"COTA, Inc, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Bai","sequence":"additional","affiliation":[{"name":"COTA, Inc, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7516-593X","authenticated-orcid":true,"given":"Christina M.","family":"Zettler","sequence":"additional","affiliation":[{"name":"COTA, Inc, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6805-0708","authenticated-orcid":true,"given":"Ming","family":"He","sequence":"additional","affiliation":[{"name":"Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX"},{"name":"COTA, Inc, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Kun","family":"Wang","sequence":"additional","affiliation":[{"name":"COTA, Inc, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.2147\/JMDH.S160029"},{"key":"e_1_3_5_3_2","unstructured":"Framework for FDA\u2019s Real-world Evidence Program 2018. https:\/\/www.fda.gov\/media\/120060\/download"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2021.100913"},{"key":"e_1_3_5_5_2","unstructured":"US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) and Oncology Center for Excellence (OCE): Real-World Data: Assessing Electronic Health Records and Medical Claims Data To Support Regulatory Decision-Making for Drug and Biological Products Guidance for Industry. 2024. https:\/\/www.fda.gov\/media\/152503\/download"},{"key":"e_1_3_5_6_2","unstructured":"Oncology Center of Excellence: Clinical trial endpoints for the approval of cancer drugs and biologics. Center for Drug Evaluation and Research. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/clinical-trial-endpoints-approval-cancer-drugs-and-biologics"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/1475-6773.12872"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1047-2797(01)00285-X"},{"key":"e_1_3_5_9_2","article-title":"Validation of a mortality composite score in the real-world setting: Overcoming source-specific disparities and biases","author":"Lerman MH","unstructured":"Lerman MH, Holmes B, St Hilaire D, et al: Validation of a mortality composite score in the real-world setting: Overcoming source-specific disparities and biases. JCO Clin Cancer Inform 10.1200\/cci.20.00143","journal-title":"JCO Clin Cancer Inform"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/1475-6773.13669"},{"key":"e_1_3_5_11_2","unstructured":"National Center for Health Statistics: National Death Index users guide appendix A: A probabilistic scoring approach for assessing NDI match results. https:\/\/www.cdc.gov\/nchs\/data\/ndi\/NDI_Users_Guide.pdf"},{"key":"e_1_3_5_12_2","volume-title":"R: A Language and Environment for Statistical Computing","author":"R Core Team","year":"2024","unstructured":"R Core Team: R: A Language and Environment for Statistical Computing. Vienna, Austria, R Foundation for Statistical Computing, 2024. https:\/\/www.R-project.org\/"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2023.6428"}],"container-title":["JCO Clinical Cancer Informatics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/CCI-24-00233","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T20:00:24Z","timestamp":1744833624000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/CCI-24-00233"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":12,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10.1200\/CCI-24-00233"],"URL":"https:\/\/doi.org\/10.1200\/cci-24-00233","relation":{},"ISSN":["2473-4276"],"issn-type":[{"value":"2473-4276","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"2024-09-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-26","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e2400233"}}